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Objectives This study sought to assess the feasibility and safety of percutaneous edge-to-edge mi-
tral valve (MV) repair in patients with an unacceptably high operative risk.
Background MV repair for mitral regurgitation (MR) can be accomplished by use of a clip that ap-
proximates the free edges of the mitral leaﬂets.
Methods All patients were declined for surgery because of a high logistic EuroSCORE (20%) or
he presence of other speciﬁc surgical risk factors. Transthoracic echocardiography was performed
efore and 6 months after the procedure. Differences in New York Heart Association (NYHA) func-
ional class, quality of life (QoL) using the Minnesota questionnaire, and 6-min walk test (6-MWT)
istances were reported.
esults Fifty-ﬁve procedures were performed in 52 patients (69.2% male, age 73.2  10.1 years,
logistic EuroSCORE 27.1  17.0%). In 3 patients, partial clip detachment occurred; a second clip was
placed successfully. One patient experienced cardiac tamponade. Two patients developed inguinal
bleeding, of whom 1 needed surgery. Six patients (11.5%) died during 6-month follow-up (5 pa-
tients as a result of progressive heart failure and 1 noncardiac death). The MR grade before repair
was 3 in 100%; after 6 months, a reduction in MR grade to 2 was present in 79% of the pa-
tients. Left ventricular (LV) end-diastolic diameter, LV ejection fraction, and systolic pulmonary artery
pressure improved signiﬁcantly. Accompanied improvements in NYHA functional class, QoL index,
6-MWT distances, and log N-terminal pro–B-type natriuretic peptide were observed.
Conclusions In a high-risk population, MR reduction can be achieved by percutaneous edge-to-
edge valve repair, resulting in LV remodeling with improvement of functional capacity after
6 months. (J Am Coll Cardiol Intv 2012;5:105–11) © 2012 by the American College of Cardiology
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106Mitral valve regurgitation (MR) is an important clinical
issue as MR represents 30% of native valve diseases (1).
Patients with symptomatic MR have a poor prognosis, with
a 5% annual mortality rate in the absence of surgery (2).
Optimal medical management can improve symptoms of
heart failure but does not affect survival (3). Therefore,
surgery is recommended by the current guidelines for
patients with symptomatic severe MR or asymptomatic
severe MR with evidence of left ventricular (LV) dysfunc-
tion or dilation (4,5). Despite those guidelines, a recent
European survey established that one-half of these patients
are not referred for surgery, mainly because of advanced age
and the presence of comorbidity
(5,6). Mitral valve (MV) repair
is the preferred surgical strategy
whenever feasible and is associ-
ated with lower morbidity and
mortality and better preservation
of LV function, compared with
MV replacement (7). Reported
in-hospital mortality rates range
from 1% to 2% in low-risk pa-
tients, increasing up to 25% in
high-risk or elderly patients (8,9).
Therefore, new percutaneous tech-
niques are developed to avoid sur-
gery in high-risk patients. The
transcatheter edge-to-edge MV re-
pair using the MitraClip system
(Abbott Vascular, Santa Clara, Cal-
ifornia) creates a double MV orifice
by means of a clip in the mid por-
tion of the 2 leaflets andmimics the
surgical procedure introduced by
Alfieri et al. (10). The first clinical
trials with the MitraClip showed
very promising results regarding
feasibility and safety of the device,
and functional improvement of the
patient (11–13). We report the
6-month outcomes of our patient
cohort treated with this device.
Methods
Patients. Between January 2009 and November 2010, the
interdisciplinary team of cardiac surgeons and cardiologists
at our hospital evaluated 52 patients suitable for MitraClip
therapy. All patients had moderate-to-severe or severe
(grade 3 or 4) MR and were symptomatic or asymptom-
atic with LV dysfunction (ejection fraction 60%) or LV
dilation (left ventricular end-systolic diameter [LVESD]
45 mm), and consequently had an indication for interven-
Abbreviations
and Acronyms
6-MWT  6-min walk test
LA  left atrial/atrium
LV  left
ventricular/ventricle
LVEDD  left ventricular
end-diastolic diameter
LVEDV  left ventricular
end-diastolic volume
LVEF  left ventricular
ejection fraction
LVESD  left ventricular
end-systolic diameter
MR  mitral regurgitation
MV  mitral valve
NT-proBNP  N-terminal
pro–B-type natriuretic
peptide
NYHA  New York Heart
Association
QoL  quality of life
RA  right atrial
RVSP  right ventricular
systolic pressure
TEE  transesophageal
echocardiographytion according to the European Society of Cardiology TaskForce recommendation (5). In addition, all patients were at
high risk for conventional surgery (logistic EuroSCORE
20% or the presence of specific risk factors associated with
excessive morbidity and mortality). Furthermore, echocardio-
graphic parameters played a crucial role in the assessment of
the suitability for clip implantation: the coaptation length had
to be at least 2 mm, excessive calcification or cleft at the
grasping area had to be absent, and in case of a flail leaflet, the
flail gap had to be10 mm and the flail width15 mm (11).
All patients underwent a standard pre-procedural screen-
ng, containing physical examination, functional capacity
ssessment (New York Heart Association [NYHA] func-
ional class and 6-min walk test [6-MWT]), quality of life
QoL) assessment using the Minnesota questionnaire, elec-
rocardiogram, chest x-ray, laboratory measurements (in-
luding N-terminal pro–B-type natriuretic peptide [NT-
roBNP]), transthoracic echocardiography, transesophageal
chocardiography (TEE), coronary angiography, and right
eart catheterization.
Procedural technique. All procedures were performed as
reviously described (14). In brief, the clip device system is
elivered to the left atrium (LA) via a transseptal puncture,
dvanced into the LV, and then retracted during systole,
rasping the MV leaflets. This results in permanent leaflet
pproximation and creation of a double orifice. The clip is a
-mm-wide cobalt-chromium implant with 2 arms. On the
nner portion of the clip arms are small “grippers” to secure
he leaflets when the arms are closed. Correct positioning of
he clip device over the mitral orifice, perpendicular to the
ine of leaflet coaptation, above the origin of the MR jet, is
andatory to prevent clip disengagement and to obtain an
cceptable MR reduction. A second (or third) clip was placed if
urther reduction of MR was needed. The procedure was
erformed under general anesthesia and both fluoroscopic
nd TEE (2- and 3-dimensional) guidance (15).
Follow-up. All periprocedural and mid-term complications
were reported. Major complications included hemorrhage
requiring blood transfusion, occurrence of cardiac tampon-
ade, need for procedure-related surgical intervention, endo-
carditis, clip detachment, clip dislodgement/embolization,
stroke, and death. Minor complications were defined as MV
injury, device thrombosis, bleeding not requiring blood trans-
fusion, femoral arteriovenous fistula formation, and femoral
hematoma.
Post-procedural anticoagulation management was based
on an individualized protocol.
All patients were discharged on aspirin 100 mg once a
day for a period of 6 months and clopidogrel 75 mg once
a day for 1 month. In patients on oral anticoagulant
therapy before the procedure, clopidogrel was added for 1
month. Infective endocarditis prophylaxis was recom-
mended for 6 months.
Six months after the procedure, all patients underwent
clinical examination, laboratory testing, TTE, and assessment
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107of functional capacity and QoL using the NYHA functional
class, the Minnesota questionnaire, and a 6-MWT.
Echocardiographic measurements. The severity of MR at
aseline was assessed using a variety of parameters, accord-
ng to recommendations published earlier (16). At 6-month
ollow-up, MR severity was graded according to the tech-
ique described by Foster et al. (17). Severity scale of 1 to 4
sing color flow Doppler (color flow mapping) and color
ow jet area (MR jet area/LA area) appeared to be the
est reproducible parameters. Vena contracta and regur-
itant orifice were recorded if possible but not included as
arameters for MR assessment because they have not
een validated for a double-orifice valve. The MV orifice
rea was assessed using the pressure half-time method.
Other echocardiographic parameters included left ven-
ricular ejection fraction (LVEF), LVESD, left ventricular
nd-diastolic diameter (LVEDD), left ventricular end-
ystolic volume, and left ventricular end-diastolic volume
LVEDV) using the biplane Simpson’s method, LA dimen-
ion and volume, right ventricular systolic pressure (RVSP)
sing tricuspid regurgitation flow velocity, and right atrial
RA) pressure using vena cava inferior dimensions. Two expert
bservers performed the endpoint analysis.
Statistical analysis. Descriptive statistics were used to report
patients’ characteristics. Continuous variables with normal
distribution are reported as mean  SD. Median and range
were used when normal distribution was absent. Percent-
ages were used to report categorical variables. Patients’ data
before and after the procedure were compared with the
paired samples t test. All tests were 2-sided, and p  0.05
was considered statistically significant. All statistical analy-
ses were performed using SPSS software (SPSS, version
14.0 for Windows, IBM, Armonk, New York).
Results
Patient characteristics. A total of 52 patients (mean age:
3.2  10.1 years, male: 69.2%) underwent percutaneous
V repair. Demographic and clinical characteristics are
ummarized in Table 1. Overall, 81% of the study popula-
ion had congestive heart failure with advanced NYHA
unctional class and high log NT-proBNP values (mean: 7.9
.0 pg/ml). Moreover, the vast majority of patients had
everal comorbidities that contributed to high logistic
uroSCOREs (mean: 27.1  17.0%). All patients presented
ith moderate-to-severe (46.2%) or severe (53.8%) MR, mainly
econdary to cardiomyopathy (90.4%). Only 5 patients (9.6%)
ere treated because of primary degenerative MR.
Procedural and in-hospital outcome. Clip implantation was
uccessful in 53 of 55 procedures (96.4%). One clip was
laced in 46 patients (83.6%), 2 clips in 6 patients (10.9%),
nd 3 clips in 1 patient (1.8%). Three patients underwent
e-intervention to have a second clip implanted. In 2
atients, the procedure was initially unsuccessful. In the first satient, the heart appeared to be rotated in the thorax after
neumectomy. As a consequence, visualization of the sep-
um was challenging, transseptal puncture was unsuccessful,
nd the procedure was abandoned. This patient was treated
Table 1. Baseline Characteristics (N  52)
Age, yrs 73.2 10.1
Age 75 yrs 24 (46.2)
Male 36 (69.2)
BMI, kg/m2 26.5 4.9
Comorbidities
Diabetes 11 (21.2)
Hypertension 34 (65.4)
COPD 14 (26.9)
Renal insufﬁciency* 36 (69.2)
Congestive heart failure 42 (80.8)
Coronary artery disease 35 (67.3)
Atrial ﬁbrillation 25 (48.1)
Logistic EuroSCORE, % 27.1 17.0
STS score, % 10.1 7.6
NYHA functional class
II 1 (1.9)
III 39 (75.0)
IV 12 (23.1)
QoL index score 56.7 22.3
6-MWT distance, m 277 129
Medication
Loop diuretics 49 (94.2)
Aldosterone antagonists 33 (63.5)
ACEI/ARB 42 (80.8)
Beta-blockers 29 (55.8)
Oral anticoagulation 34 (65.4)
Aspirin 20 (38.5)
Laboratory ﬁndings
Hemoglobin, mmol/l 7.9 1.0
Creatinine, mol/l 135.0 52.5
Log NT-proBNP, pg/ml 7.9 1.0
ECG
Rhythm (SR/AF/PM), % 46.2/28.8/25.0
QRS width, ms 137.1 31.9
LBBB 13 (25.0)
MR severity
3 (moderate-to-severe) 24 (46.2)
4 (severe) 28 (53.8)
MR etiology
Functional 47 (90.4)
Ischemic 31 (59.6)
Nonischemic 16 (30.8)
Degenerative 5 (9.6)
Values aremeanSDorn (%). *Definedas estimatedglomerular filtration rate60ml/min/1.73m2.
6-MWT 6-min walk test; ACEI angiotensin-converting enzyme inhibitor; AF atrial fibril-
lation; ARB angiotensin-II receptor blocker; BMI body mass index; COPD chronic obstruc-
tive pulmonary disease; ECG electrocardiogram; LBBB left bundle branch block; MRmitral
regurgitation NYHA New York Heart Association; PM  pacemaker rhythm; QoL  quality of
life; SR sinus rhythm; STS Society of Thoracic Surgeons.uccessfully 1 month later after anatomical assessment with
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108magnetic resonance imaging (suspicion of triatrial heart). In
a second patient, no clip was placed because the MR jet was
located too far medial to accomplish a satisfactory leaflet
apposition. He was treated conservatively. One patient died
in the course of a so-called “rescue-clip” procedure as a
result of cardiogenic shock and acute heart failure. This
66-year-old male with an LVEF of 15%, underwent the
second clip procedure 4 months after the first, because of
severe MR with heart failure after a non–ST-segment
elevation myocardial infarction. Another patient with di-
lated cardiomyopathy and pulmonary hypertension died 8
days after the procedure because of end-stage heart failure.
In this patient, a total of 3 clips were implanted, of which 1
partially detached from the posterior leaflet during the
procedure. Partial clip detachment occurred in another
patient before discharge, a second clip was placed success-
fully 1 week later. In 1 patient, we punctured the LA wall
during the first attempt to gain transseptal access. The
second transseptal puncture, as well as clip implantation
thereafter, was successful. During the procedure, we did not
observe pericardial effusion. Unfortunately, 2 h after the
procedure, the patient developed clinical signs of cardiac
tamponade requiring subxyphoidal drainage. Two patients
suffered from femoral bleeding at the puncture site, 1
needed surgery. In another patient, an iatrogenic pharyngeal
bleeding (requiring blood transfusion) occurred as a result of
TEE probe manipulation. Procedural characteristics and
Table 2. Procedural and In-Hospital Characteristics
Procedures, n 55*
Successful clip implantation 53 (96.4)
Clips per procedure
0 2 (3.6)
1 46 (83.6)
2 6 (10.9)
3 1 (1.8)
Procedure time, min 147.7 69.9
Radiation time, min 42.3 21.9
Radiation dose, Gy/cm2 185.7 116.9
Length of hospital stay, days 5 (3–15)†
Length of intensive care stay, days 1 (1–6)†
In-hospital complications
Death 2 (3.6)‡
Cardiac 2 (3.6)
Noncardiac 0 (0)
Cardiac tamponade 1 (1.8)
Transseptal complications 1 (1.8)
Procedure related surgical intervention 1 (1.8)
Bleeding requiring transfusion 2 (3.6)
Partial clip detachment 2 (3.6)‡
Clip embolization 0 (0)
Values are n (%) ormean SD. *In 52 patients.†Values aremedian (range).‡1 death and 1 partial
clip detachment occurred in the same patient.in-hospital complications are listed in Table 2.Mid-term clinical outcome. Clinical follow-up data were
vailable in 48 patients. One patient moved abroad and was
ost to follow-up. Overall 6-month mortality was 11.5%. In
ddition to the 2 in-hospital deaths, 4 other patients died
uring follow-up. One patient died of noncardiac cause. All
thers died as a result of progressive heart failure. Six other
atients (12.5%) were rehospitalized because of worsened
eart failure, needing intravenous diuretic and/or inotropic
herapy. Two of these patients received a cardiac resynchro-
ization device with defibrillator during this admission.
nother patient presented with ventricular fibrillation orig-
nating from an old myocardial scar; a cardiac resynchroni-
ation device with defibrillator was implanted. Complications
uring follow-up are shown in Table 3. Paired clinical data
t baseline and follow-up could be obtained in most patients
Table 4). NYHA functional class diminished significantly
rom a median of 3 (range: 3 to 4) to 2 (range: 1 to
) (p  0.001), and 84% of the patients with clinical
ollow-up was in NYHA functional class I or II (Fig. 1).
ive patients (11.4%) did not improve in NYHA functional
lass. A QoL index score reduction from 56.5  21.9 to
9.4  20.5 (p  0.001) was observed. Furthermore, log
T-proBNP decreased from 7.7  1.0 pg/ml to 7.1  1.2
pg/ml (p  0.001). Because of the improved functional
capacity, 6-MWT distances increased from 300 108 m to
39  120 m (p  0.02).
Impact on MR and LV remodeling. Echocardiographic
follow-up could be performed in 42 patients (80.8%). Data
are summarized in Table 4. Overall, 40 of 42 patients
(95.2%) had a reduction in MR of 1 grade. Only 2
patients did not improve and remained at grade 3MR. In
79% of the patients, a reduction in MR grade to 2 was
achieved (Fig. 2). Subsequently, RA pressure and RVSP
dropped significantly. No clinical or echocardiographic
signs of MV stenosis were observed during follow-up.
Compared with baseline, LVEF improved significantly
from 36.6  14.1% to 39.3  14.2% (p  0.05). LVEDD
decreased from 63.9  10.3 mm to 61.9  10.2 mm (p 
0.01). The LV volumes decreased nonsignificantly.
Table 3. Clinical Events During 6-Month Follow-Up (N  48)
Complications
Death 4 (8.3)
Cardiac 3 (6.3)
Noncardiac 1 (2.1)
Mitral valve surgery 0 (0)
Stroke 0 (0)
Mitral valve endocarditis 0 (0)
Partial clip detachment 1 (2.1)
Clip embolization 0 (0)
Rehospitalization for heart failure 6 (12.5)
Values aren (%). 2 patients died inhospital, 1 patientwas lost to follow-up, and in 1patient, no clipwas placed.
abbrevi
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 5 , N O . 1 , 2 0 1 2 Van den Branden et al.
J A N U A R Y 2 0 1 2 : 1 0 5 – 1 1 Mitral Valve Clip Repair in High-Risk Patients
109Discussion
We report the largest single-center experience for percuta-
neous edge-to-edge MV repair in a high-surgical-risk pop-
ulation. Our results indicate that this technique can be
accomplished with favorable mid-term outcomes with an
Table 4. Paired Comparison of Baseline and 6-Month
n
NYHA functional class 44
QoL index score 44
6-MWT distance, m 31
Log NT-proBNP, pg/ml 38
Echocardiographic parameters 42
LVEDD, mm
LVESD, mm
LVEDV, ml
LVESV, ml
LVEF, %
LA volume index, ml/BSA
LA dimension, mm
MR grade
MR/LA area, %
RVSP, mm Hg
RA pressure, mm Hg
Mean transmitral gradient, mm Hg
Mitral valve oriﬁce area, cm2
Values are median (range) or mean SD.
6-MWT  6-min walk test; LA  left atrial; LVEDD  left ventricu
LVEDV left ventricular end-diastolic volume; LVEF left ventricular e
RVSP right ventricular systolic pressure; QoL quality of life; other
23
2
75
14
59
25
2
0%
20%
40%
60%
80%
100%
NYHA baseline (n=52) NYHA 6 months (n=44)
NYHA I
NYHA II
NYHA III
NYHA IV       
    
  
Figure 1. Change in NYHA Functional Class
At baseline, 98% of the patients was in New York Heart Association (NYHA)
functional class III or IV. Six months after clip repair, 84% of the patients
was in NYHA functional class I or II.increase in functional capacity and improvement in echo-
cardiographic parameters.
Patients with severe symptomatic MR might develop
progressive heart failure, which is often refractory to medical
therapy. Without intervention, these patients have an an-
nual rate of death of 5% or more (18). Especially for patients
with functional MR and poor LV function, there are no
widely accepted indications for surgery other than as a
tional and Echocardiographic Characteristics
Baseline 6 Months p Value
3 (3–4) 2 (1–4) 0.001
56.5 21.9 39.4 20.5 0.001
300 108 339 120 0.02
7.7 1.0 7.1 1.2 0.001
63.9 10.3 61.9 10.2 0.01
54.0 12.8 52.9 13.0 0.35
184.0 72.4 172.9 83.9 0.08
123.2 65.3 114.4 74.7 0.07
36.6 14.1 39.3 14.2 0.05
62.6 23.8 49.8 20.1 0.001
49.4 6.3 49.0 7.9 0.70
4 (3–4) 1 (1–3) 0.001
50.7 15.5 26.4 13.1 0.001
38.8 13.1 31.1 10.9 0.001
7.9 3.8 5.0 3.8 0.005
— 3.8 2.0 —
— 2.9 0.8 —
-diastolic diameter; LVESD  left ventricular end-systolic diameter;
fraction; LVESV left ventricular end-systolic volume; RA right atrial;
ations as in Table 1.
54
46
21
26
53
0%
20%
40%
60%
80%
100%
MR grade baseline (n=52) MR grade 6 months (n=42)
1
2
3+
4       
    
  
Figure 2. Change in MR Grade
At baseline, all patients had moderate-to-severe (grade 3) or severe mitral
regurgitation (MR). Six months after clip implantation, 79% of the patientsFunc
lar end
jectionhad MR grade 2.
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110concomitant procedure at the time of bypass surgery, but its
benefits have been variable and outcomes suboptimal
(4,5,19,20). The periprocedural mortality rates described in
surgical series varies between 2.1% and 11% in patients with
depressed LV function, and as high as 25% in very high-risk
or elderly patients (21,22). In our study, including high-risk
patients with poor LV function, we report an in-hospital
mortality of 3.8%. Two patients who were treated in our
early experience phase died in-hospital as a result of end-
stage heart failure. After reviewing those cases, we must
conclude that the risk–benefit ratio for percutaneous repair
was suboptimal. Therefore, a stringent selection process is
mandatory, including a guideline-supported indication for
intervention and extensive pre-procedural echocardio-
graphic assessment. Clinical patient characteristics associ-
ated with worse outcome are yet to be determined. In the
presence of myocardial fibrosis and irreversible LV adverse
remodeling, MR reduction may not provide any benefit
(19,23). It has been shown that the degree of LV contractile
reserve as assessed by exercise or inotropic stimulation is a
predictor of LV function after MV repair (24,25). There-
fore, gadolinium-enhanced and dobutamine stress magnetic
resonance imaging might be helpful for patient selection.
In the recently published EVEREST II (Endovascular
Valve Edge-to-Edge Repair Study II), 279 patients were
randomized in a 2:1 ratio to undergo clip therapy or open
MV surgery and showed no difference in mortality (6% in
both groups) at 12-month follow-up (26). Noteworthy, in
this trial, MR of degenerative origin was predominant
(73%), and mean LVEF was 60.0  10.1% in the clip
group. In the present study, the overall 6-month mortality
rate was 11.5%. However, the mean LVEF was 37%, with
a predicted periprocedural mortality rate of 27%.
Recently, Franzen et al. (27) showed the effectiveness of
MV clip therapy in an end-stage heart failure population. In
this multicenter study, 50 patients (LVEF 25%, mean
logistic EuroSCORE: 34%) with functional MR were
included, and at 6-month follow-up, MR 2 was present
in 87% of the patients. In the EVEREST II trial, surgery
appeared to be more effective in reducing MR compared
with percutaneous repair. However, in the subgroup with
functional MR (27% in both groups), surgery was not
superior (26). In our study population, including 90%
functional MR, a reduction in MR of 1 grade was
achieved in 95%, and 79% of the patients had MR grades
2, 6 months after the procedure (11–13). Despite the LV
geometric distortion with concomitant annular dilation in
most of our patients, clip placement was successful in
96%, which is comparable with the report by Franzen et
al. (27). Taken together, patients with functional MR can
be treated successfully and seem to benefit most from this
new technique. Moreover, Maisano et al. (28) reported
that isolated surgical edge-to-edge repair has acceptable
outcomes for both degenerative and functional MR witha 5-year freedom from recurrent MR 2 and reopera-
tion of 90%.
As a result of MR reduction, we observed diminished
plasma NT-proBNP levels, accompanied with significant
improvements in QoL and functional capacity, which may
be the primary goal in this challenging high-risk population.
The improvement in objective parameters shows that the
observed clinical effect can be attributed to improvements
beyond a placebo effect. NYHA functional class improved
in 89% of our population, which is in line with previous
reports (11,27). The EVEREST II trial showed similar
improvements in NYHA functional class and QoL in both
the clip and surgery subgroups at 12 months (26).
Of note, percutaneous MV repair seems to be associated
with positive reverse LV remodeling. We report a signifi-
cant increase in LVEF, decrease in LVEDD, and obvious
improvements in LV volumes. The question remains
whether this will affect long-term prognosis, as previous
reports showed no evidence that surgery for functional MR
prolongs life, despite LV reverse remodeling (29,30).
Our findings underline the growing understanding that
percutaneous approaches become a valuable treatment op-
tion for an important number of patients with severe
(especially functional) MR who cannot undergo surgery
(31). In the future, the field of percutaneous transcatheter
MV repair will undoubtedly evolve exponentially. In our
opinion, because functional MR is primarily a disease of the
LV, a combination of the edge-to-edge repair with other
percutaneous techniques addressing the annulus and the LV
itself will be necessary to provide durable correction and
satisfactory long-term outcomes (32).
Study limitations. First, we acknowledge the observational,
nonrandomized nature of the study and the relative small
number of patients. However, we continue to treat patients
not eligible for surgery and will perform long-term
follow-up to determine the true value of this new approach.
Another limitation is that the follow-up echocardiograms
could not be reviewed in a blinded or independent way.
Furthermore, we assessed MR severity after clip placement
only by MR jet area and the MR/LA jet ratio. However,
comparing these parameters pre- and post-procedure should
provide a reliable perception of MR reduction.
Conclusions
Percutaneous edge-to-edge mitral valve repair seems to be a
valuable alternative for patients with severe, symptomatic
MR who are not candidates for open MV surgery. We
observed important reductions in MR grade in most pa-
tients that contributed to positive LV remodeling with
improvement of QoL and functional capacity. However,
careful patient selection seems obligatory, especially in case
of advanced heart failure.
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